Immunovant (IMVT) market cap

Market cap today
$6.86B

Immunovant (IMVT) has a market cap of $6.86B. At the end of fiscal 2026 (March 31, 2026) its market cap was $4.53B. That is 74.9% higher than the $2.59B of fiscal 2025. Today's figure is 51.5% above the fiscal 2026 year-end. Figures as of 19 Nov 2026, 03:10 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Market cap today
$6.86B
Market cap, fiscal 2026
$4.53B
Change on fiscal 2025
+74.9%
Growth, 5 years
+26.3% a year
Highest on record
$4.53Bfiscal 2026
Lowest on record
$604.33Mfiscal 2022
Fiscal years on record
62021–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Immunovant market cap, in more detail

Over the five fiscal years to 2026 the market cap grew at a compound 26.3% a year. Across the 6 fiscal year-ends on record (2021–2026), the highest was $4.53B in fiscal 2026 and the lowest $604.33M in fiscal 2022.

History · 6 fiscal years

Market cap at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Immunovant market cap, year by year

Immunovant (IMVT) market cap by fiscal year
Fiscal yearMarket capChangeYear endedShare price at year-endDiluted shares
Today$6.86B—$33.17—
2026$4.53B 74.9% up$24.84182.42M
2025$2.59B 41.9% down$17.09151.57M
2024$4.46B 133.7% up$32.31138.10M
2023$1.91B 215.9% up$15.51123.08M
2022$604.33M 57.1% down$5.51109.68M
2021$1.41B—$16.0487.76M
2020——$15.56—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Market cap is the share price multiplied by the number of shares: for past years this page multiplies the diluted share count in each annual report by the closing price for the month that fiscal year ended in, and today's figure comes from the live quote.

How to read it

It is what the stock market says the whole company is worth — a measure of size, not of whether the shares are cheap or dear.

More on IMVT

Immunovant, figure by figure

Immunovant (IMVT) overview: price, valuation and scorecardAll health care companies by market value

Immunovant market cap: questions and answers

What is Immunovant's market cap?

Immunovant (IMVT) has a market cap of $6.86B. At the end of fiscal 2026 (March 31, 2026) its market cap was $4.53B. That is 74.9% higher than the $2.59B of fiscal 2025.

What is the growth rate of Immunovant's market cap?

Over the five fiscal years to 2026 the market cap grew at a compound 26.3% a year.

What are the highest and lowest market cap figures on record for Immunovant?

Across the 6 fiscal year-ends on record (2021–2026), the highest was $4.53B in fiscal 2026 and the lowest $604.33M in fiscal 2022.

How is Immunovant's market cap calculated?

Market cap is the share price multiplied by the number of shares: for past years this page multiplies the diluted share count in each annual report by the closing price for the month that fiscal year ended in, and today's figure comes from the live quote. For Immunovant it is on record here for 6 fiscal years, 2021 to 2026.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Immunovant (IMVT) market cap”, data as of 19 November 2026. https://funkfolio.com/stock/IMVT/market-cap

Underlying data: the company's filings with the SEC and Yahoo Finance.